Aptinyx Inc reported $66.58M in Cash and Equivalent for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US USD 436.58M 296.75M
Acorda Therapeutics ACOR:US USD 20.7M 2.43M
Biogen BIIB:US USD 3.68B 1.03B
Cara Therapeutics CARA:US USD 42.81M 3.91M
Daiichi Sankyo 4568:JP JPY 480.22B 177.84B
Eli Lilly And LLY:US USD 2.62B 5.5M
Halozyme Therapeutics HALO:US USD 147.16M 56.23M
Intra Cellular Therapies ITCI:US USD 135.36M 58.12M
IONIS PHARMACEUT IONS:US USD 314.99M 206.92M
Marinus Pharmaceuticals MRNS:US USD 168.25M 75.92M
Neurocrine Biosciences NBIX:US USD 212.2M 48.9M
Novartis NOVN:VX USD 8.73B 5.1B
Ultragenyx Pharmaceutical RARE:US USD 391.65M 231.78M
Vertex Pharmaceuticals VRTX:US USD 9.17B 469.3M